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Abstract 
Ceftazidime-avibactam is a novel β-lactam/β-lactamase inhibitor combination for the treatment of 
serious infections caused by resistant Gram-negative pathogens. Population pharmacokinetic (PK) 
models were built to incorporate PK data from five Phase III trials in patients with complicated intra-
abdominal infection, complicated urinary tract infection or nosocomial (including ventilator-
associated) pneumonia. Ceftazidime and avibactam PK were well-described by two-compartment 
disposition models, with creatinine clearance (CrCL) the key covariate determining clearance 
variability. Steady-state ceftazidime and avibactam exposure for most patient subgroups differed by 
≤20% versus healthy volunteers. Probability of PK/pharmacodynamic target attainment (free plasma 
ceftazidime >8 mg/mL and avibactam >1 mg/mL for ≥50% of dosing interval) was ≥94.9% in 
simulations for all patient subgroups, including indication and renal function categories. No 
exposure-microbiological response relationship was identified because target exposures were 
achieved in almost all patients. These modelling results support the approved ceftazidime-avibactam 
dosage regimens (2000/500 mg every 8 hours, adjusted for CrCL ≤50 mL/min). 
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Introduction 
There is an urgent need for new antimicrobial treatments to combat increasing antimicrobial 
resistance1 among Gram-negative pathogens such as Enterobacteriaceae and Pseudomonas 
aeruginosa, which are frequently involved in serious bacterial infections.2-4 Avibactam is a first-in-
class novel non-β-lactam β-lactamase inhibitor, which restores the in vitro activity of β-lactams, 
including ceftazidime, against Ambler class A, class C, and some class D β-lactamase-producing 
pathogens,5-7 including those producing Klebsiella pneumoniae carbapenemase and OXA-48 
carbapenemases, but not metallo-β-lactamases.8-10 Ceftazidime-avibactam is approved in both the 
USA and Europe for the treatment of adults with cIAI ([complicated intra-abdominal infection] in 
combination with metronidazole), cUTI ([complicated urinary tract infection] including 
pyelonephritis), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP).11, 
12 
Ceftazidime-avibactam has been extensively studied in Phase II13, 14 and III clinical trials in adult 
patients with cIAI (n=857) and cUTI (n=731), including in patients with infections caused by 
ceftazidime-non-susceptible organisms,15-18 and in a Phase III trial in patients with nosocomial 
pneumonia (NP) including VAP (n=436).19 These trials each included sparse pharmacokinetic (PK) 
sampling protocols, and these patient PK data were used to develop and update the ceftazidime and 
avibactam population PK (PopPK) models iteratively during clinical development.20-22 Early models 
using data from healthy subjects and Phase II studies 20 were updated in subsequent iterations with 
Phase III data as these became available.21, 22 Covariate effects were broadly consistent throughout 
the iterations and the main factors explaining variability in exposure of both ceftazidime and 
avibactam were patient population (patients versus healthy subjects) and creatinine clearance 
(CrCL), a surrogate for renal function.20-22 Both ceftazidime and avibactam concentration-time 
courses were well-described by a linear two-compartment PK model. These early models were 
used in Monte Carlo simulations and probability of target attainment (PTA) analyses to support 
selection of ceftazidime-avibactam dosage regimens in Phase III trials, including in patients with 
various levels of renal function. The early models also supported the initial 2015 US Food and Drug 
Administration approval of ceftazidime-avibactam in cIAI and cUTI including pyelonephritis, thereby 
enabling an expedited approval pathway, which has subsequently been recognized by European 
regulatory authorities.23, 24 
The PopPK analyses described here, which incorporate data from the ceftazidime-avibactam Phase 
III trials across all indications, evaluate the actual performance of the ceftazidime-avibactam dosage 
regimen used in these trials by (1) determining the impact of patient characteristics of potential 
clinical interest on ceftazidime and avibactam PK and (2) evaluating PTA against a range of 
pharmacodynamic (PD) targets in patients with cIAI, cUTI, and NP including VAP, and in different 
clinical scenarios, including various levels of renal function. 
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Methods 
Analysis data and model construction 
PopPK datasets were assembled for ceftazidime and avibactam using data from four Phase III cIAI or 
cUTI trials (RECLAIM 1 and 2 [analyzed as a single trial with one database],15 and RECLAIM 3;15, 16 
RECAPTURE 1 and 2 [analyzed as a single trial with one database];17 REPRISE18), one Phase III NP trial 
(REPROVE), two Phase II trials (cIAI;13 cUTI14), and 11 Phase I trials. All trials were conducted in 
accordance with the Helsinki Declaration of 1975 (as revised in 1983) and approved by 
local/institutional ethics committees. 
The datasets included healthy volunteers and patients, and the PopPK modelling utilized individual 
baseline covariate information, chronological records of serum creatinine (for CrCL calculations) and 
the full dosing and plasma sampling history. The range of estimated CrCL (Cockcroft-Gault equation) 
in the ceftazidime dataset was 8–488 mL/min. The avibactam dataset included subjects with normal 
renal function to end-stage renal disease (ESRD), as well as subjects with sepsis and augmented 
renal clearance (ARC, defined as measured CrCL ≥140 mL/min [8 h urine collection] and specific to 
study CXL-PK-04 [Table S1]); the estimated CrCL range was 11–610 mL/min. 
Ceftazidime-avibactam plasma concentration-time data were analyzed using nonlinear mixed effects 
modelling, which in earlier PopPK analyses described the PK of both ceftazidime and avibactam as a 
two-compartment disposition model with first-order elimination from a central compartment 
following IV infusion, parameterized by CL, volume of the central compartment (Vc), inter-
compartmental clearance (Q), and volume of the peripheral compartment (Vp).22 The first-order 
conditional estimation with interaction (FOCE-INTER [FOCE-I]) method in NONMEM version 7.2 
(Hanover, MD, USA) was used for model building. The previous models (including covariates) were 
run with the updated data set including patients from REPROVE, and the population effect for NP 
patients on Vc and CL was added. Outliers (conditional weighted residual error >4) were excluded 
prior to covariate model building. As the ceftazidime dataset lacked data for subjects with severe 
renal impairment, it was necessary to incorporate individual estimates of ceftazidime CL from 
patients with renal insufficiency reported in the literature into the base model (Supplementary 
Methods). 
After covariate model building completion, which included assessment of additional covariates and 
refinement of previous covariate effects, different structures of the variance covariance matrix of 
random effects were evaluated. The final PopPK models were then rerun with and without outliers. 
Abnormally high ceftazidime concentrations (>750 mg/mL) were excluded from the final model. To 
further improve prediction of the observed data at the 10th percentile, the final models were re-
estimated with the Stochastic Approximation Expectation Maximization method with Importance 
Sampling. 
Selection of covariates 
Covariate selection was performed using a forward-addition process followed by backward deletion 
(i.e. stepwise covariate model [SCM]). Covariates tested included: disease status/indication (e.g. NP, 
VAP or cIAI), ARC (specific to study CXL-PK-04 [Table S1], with subjects in other studies classified as 
non-ARC), markers of systemic disturbances (e.g. white blood cell [WBC] count ≤12000/μL, presence 
of fever, systemic inflammatory response syndrome or bacteremia, Acute Physiology and Chronic 
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Health Evaluation version II [APACHE II>10], sex, age, obesity status and body weight, race, 
CrCL/ESRD, dialysis, study phase, geographic region and NP with ventilation on the day of PK 
sampling (NPv, recorded as the presence of a ventilator in the hospital room, which includes patients 
with VAP or HAP who were ventilated on the day of PK sampling). The APACHE II score is an 
integrated measure of disease severity for intensive care patients, with higher scores signifying 
greater disease severity. Predicted mortality rises steeply for scores >10 (>10% mortality), and this 
represents a reasonable cut-off for defining more severely ill patients.25 The effect on avibactam PK 
of concomitant administration of organic anion transporter 1 (OAT1) and OAT3 inhibitors 
(probenecid, cimetidine and diclofenac) was also evaluated, given that avibactam is a substrate for 
these transporters in vitro.26 
Covariate effects with significance levels of p=0.01 during forward inclusion were carried forwards 
for backward elimination testing with an acceptance criterion of p=0.001. All covariates identified as 
being statistically significant during model building were subjected to clinical relevance criteria. 
Categorical covariates that resulted in <20% change relative to reference in the associated 
parameter, and continuous covariates that did not result in a ≥20% difference in the associated 
parameter at the 5th and/or 95th percentiles of the covariate relative to the covariate median, were 
generally deemed clinically irrelevant and dropped from the final model.  Exceptions were made for 
covariates of particular clinical interest with <20% impact, or where the effect size was close to 20%. 
 
Model evaluation 
Standard diagnostic plots were used throughout model development to assess the ability of each 
model to describe the observed data, including observed versus individual (IPRED) and population 
(PRED) predicted concentrations, and weighted residuals (WRES)/conditional WRES/individual WRES 
versus PRED or time. 
Bootstrap re-sampling techniques were used to evaluate the stability of the final model and to 
estimate non-parametric confidence intervals (CIs) for the model parameters. The same set of 
subjects as in the analysis dataset were used to generate 200 bootstrapped data sets. The median 
and 90% CIs of the PK parameter estimates fitted to these 200 resampled data sets were compared 
to the original PK estimates from the final model. 
Visual predictive checks (VPCs) were used to evaluate the predictive performance of the final model. 
A prediction-corrected VPC (pcVPC) was performed using the VPC algorithm in Perl-speaks-
NONMEM (PsN) v3.7.6. A total of 1,000 replicates (i.e. datasets) were simulated using the final 
models. Within each simulated replication the 10th, 50th and 90th percentiles of the simulated 
concentrations were computed by the nominal sampling time. By taking the 10th and 90th 
percentiles of the within-replicate statistic values, a 90% CI for each statistic was derived. Model 
performance was assessed based on the perceived congruence between the model-derived CIs and 
the observed data. 
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PK parameter calculations and simulations in Phase III patients 
Empirical Bayes estimates of individual PK parameters for all Phase III subjects were used to derive 
secondary parameters e.g. maximum plasma concentration at steady state (Cmax ss) and area under 
the plasma concentration-time curve at steady-state (AUCss,0–24). Cmax,ss and AUCss,0–24 for ceftazidime 
and avibactam were calculated for subgroups of clinical interest to verify acceptable exposure. 
Concentration-time courses of ceftazidime and avibactam were simulated for Phase III patients with 
≥1 PK sample in the final PopPK datasets using observed CrCL taken closest to the PK sampling day 
(Day 3). These were used to calculate individual PK/PD target attainment in Phase III subjects as 
described below. 
 
PK/PD targets  
A joint PK/PD target for ceftazidime and avibactam was employed to assess the suitability of the 
Phase III dosage regimens. The joint target was defined as simultaneous achievement of 50% time 
(during each dosing interval) free plasma concentrations exceed ceftazidime-avibactam minimal 
inhibitory concentration (MIC) of 8 mg/L for ceftazidime (50% fT>8 mg/L), and 50% fT above a 
threshold concentration (CT) of 1 mg/L for avibactam (50% fT>1 mg/L).27 50% fT>MIC is a an 
established PK/PD target for ceftazidime and other cephalosporins;28-31 a target of 8 mg/L was 
chosen based on global surveillance studies where a ceftazidime-avibactam MIC of ≤8 mg/L was 
observed to include ≥90% of clinical isolates of Enterobacteriaceae and P. aeruginosa.32-36 For 
avibactam, the PK/PD index was derived from hollow fiber and murine models of infection and 
determined as %fT>CT.37-39 In hollow fiber experiments using various strains of ceftazidime-resistant 
Enterobacteriaceae with fixed concentrations of ceftazidime and varying concentrations of 
avibactam, CT values of 0.15 to 0.28 mg/L were sufficient to restore ceftazidime activity; when the 
concentration of avibactam was fixed in the presence of varying concentrations of ceftazidime, a CT 
≤0.5 mg/L restored the activity of ceftazidime.37 In neutropenic mouse thigh and lung infection 
models using various strains of ceftazidime-resistant P. aeruginosa, %fT>1 mg/L values of 
approximately 16–24% were associated with stasis, and values of approximately 20–55% were 
associated with 2log10 reductions in bacterial denisty.38 Accordingly, the avibactam target CT value 
for both Enterobacteriaceae and P. aeruginosa was set to 1 mg/L.27 
The joint PK/PD target was applied to the predicted PK profiles in Phase III patients to determine 
individual target attainment, and was also used in PTA simulations. There was no relationship 
between CT and MIC for any of the bacterial strains tested.37-39 However, to further explore the 
performance of the Phase III ceftazidime-avibactam dosage regimens, a sensitivity analysis of more 
conservative joint PK/PD targets was also evaluated in PTA simulations. 
 
Exposure-response analysis 
PK target attainment analyses used free plasma concentrations (taken to be 85% and 92% of total 
plasma concentrations for ceftazidime and avibactam, respectively). To explore exposure-response 
relationships by indication, estimates of %fT>MIC ceftazidime, %fT>MIC ceftazidime-avibactam, and 
%fT>CT for avibactam, were calculated from simulated ceftazidime and avibactam profiles. %fT>MIC 
(2, 4, and 8 mg/L) for ceftazidime and %fT>CT (0.5, 1, 2, and 4 mg/L) for avibactam were also 
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estimated to explore fully target attainment for the approved doses using a range of targets beyond 
those determined from nonclinical studies. Logistic regression of overall microbiological response 
(OMR) as a function of each exposure metric was conducted for patients with both baseline MIC 
data and ceftazidime and avibactam exposure metrics. In addition to the above dichotomous 
targets, a continuous endpoint, defined as %fT >MIC COR, was also evaluated for its potential utility 
in predicting clinical outcome. MIC COR is an avibactam-corrected ceftazidime MIC calculated as a 
function of the avibactam concentration and the MIC of ceftazidime against a pathogen evaluated in 
the presence and absence of 4 mg/L avibactam, and fluctuates over time in conjunction with 
avibactam exposure. 
 
Exposure and PTA simulations 
PTA simulations were based on the final PK models for ceftazidime and avibactam developed using 
pooled data from the Phase III RECLAIM, REPRISE, RECAPTURE and REPROVE trials. To account for 
the correlation between ceftazidime and avibactam random effects, the random effects were 
bootstrapped using the approaches detailed in the supplement. To avoid any bias in PTA caused by 
shrinkage towards the median of post-hoc parameters and ensure the results were conservative, the 
random effects were inflated by a factor inversely proportional to the estimated shrinkage. 
PTA simulations were conducted for 5,000 simulated patients for each indication and renal function 
group. Covariate records for 5,000 simulated patients were obtained by sampling with replacement 
from Phase III patients in each population that had normal renal function on the PK day (i.e. CrCL >80 
mL/min). Simulations incorporated covariate distributions appropriate to each patient population 
and between-patient variability, but excluded residual error and uncertainty in the population 
parameters. For cIAI, simulations were performed for all patients, Chinese patients, and non-
Chinese, non-Japanese Asians. For NP, simulations were for all NP patients, only patients with VAP, 
only non-VAP patients, and only NPv patients. Simulations were also performed for cUTI, NP 
including VAP, non-VAP and NPv for Chinese patients and/or non-Chinese, non-Japanese Asians. 
Simulations of patients with renal impairment were for label-recommended dosage adjustments by 
category, and CrCL values were assumed to follow a uniform distribution within the designated 
range for each category. 
 
Results 
Analysis populations 
An overview of the clinical studies included in the PopPK models is provided in Table S1. The final 
ceftazidime dataset included 9,155 observations from 1,975 adult subjects: 86 healthy subjects 
(4.4%), 696 cUTI patients (35.2%), 781 cIAI patients (39.5%) and 412 (20.9%) NP patients. The final 
avibactam dataset included 13,735 observations from 2,249 subjects: 345 healthy subjects or 
subjects with renal impairment from Phase I studies (15.3%), 705 cUTI patients (31.3%), and 786 cIAI 
patients (34.9%) and 413 NP patients (18.4%). Demographic data are summarized in Tables S2 and 
S3. 
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Final population PK models 
The ceftazidime and avibactam PopPK data were well-described by a two-compartment disposition 
model. Parameter estimates from the final models are shown in Tables 2 and 3; equations for the 
covariate relationships are in the Supplementary Results. Parameter estimates from the full analysis 
datasets differed from the median bootstrap estimates by <20% except for intercompartmental 
clearance for ceftazidime, and the parameter estimates from bootstrapping were within the CIs 
(Tables S4 and S5). PcVPCs (Figures 1, 2, and S1–S8) demonstrated that the final models reflected 
the observed data and were suitable for use in simulations. Goodness-of-fit plots for ceftazidime and 
avibactam (Figures S9 and S10) showed that the models exhibited minimal bias. 
 
Ceftazidime 
CrCL was the key covariate predicting ceftazidime CL (Table 1). The relationship was close to 
proportional at CrCL<100 mL/min; for CrCL≥100 mL/min the regression slope of ceftazidime CL 
versus CrCL was very shallow (12.5% increase in CL per 100 mL/min increase in CrCL above 100 
mL/min). No other covariate effects on CL in Phase III patients exceeded the predefined threshold 
for clinical relevance (±20%). Noteworthy small covariate effects on ceftazidime CL that were 
retained in the final model (as exceptions to the general rule) were indication (16% higher CL for cIAI 
patients versus healthy subjects and cUTI patients) and racial/regional origin (Chinese patients had 
9% lower CL and non-Chinese, non-Japanese Asians 16% lower CL than non-Asians). 
The covariate effects on ceftazidime Vc that were included in the final model were: 
indication/indication subgroups, Asian race, body weight, pyelonephritis and NPv (Table 1). 
Estimated effects exceeding ±20% were: a 27% lower Vc for Asian compared with non-Asian patients; 
a 29.7% higher Vc for NPv patients than for non-NPv patients; a 24% lower and 26% higher Vc for 
patients with body weight at the 10th percentile (50 kg) and 90th percentile (94 kg), respectively, 
compared with those of median weight (70 kg). 
All fixed effect parameters were estimated with good precision, with all relative standard errors 
(RSEs) <27% except for the effect of acute pyelonephritis on Vc (41.2%) and the effect of NPv on Vc 
(45.4%). Inter-individual random effects with a correlation parameter estimated between CL, Vc, Vp 
and Q were also well estimated, with %RSEs generally <16%. 
 
Avibactam 
CrCL was the key covariate predicting the CL of avibactam (Table 2). For patients with CrCL <80 
mL/min, CL dependence on CrCL was estimated as a power function of 1.05 indicating an 
approximately linear relationship. For patients with CrCL ≥80 mL/min, the relationship between CL 
and CrCL was modelled as a shallow linear function such that avibactam CL increased by 27.9% for 
an increase of 100 mL/min in CrCL over 80 mL/min. For ESRD patients, CL was 0.0678 L/h off dialysis 
and 20.8 L/h on-dialysis. The largest covariate effect on CL in Phase III patients aside from renal 
function was a 19.7% decrease for APACHE II score >10. Also noteworthy was an estimated 8.65% 
lower CL (translating to a 9.5% increase in AUC) for non-Chinese, non-Japanese Asians compared 
with that for patients of other racial origins and this covariate was also retained in the final model. 
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The covariate effects on avibactam Vc that were retained in the final model and relevant to Phase III 
subjects were body weight, indication, and NPv status (Table 2). Subjects at the 10th (51 kg) or 90th 
percentile of body weight (95 kg) had estimated Vc respectively 29% lower or 39% higher than the 
median weight (70 kg). The Vc was 32.9% and 43.4% higher for Phase III cIAI and NP patients and 
cUTI patients, respectively compared with healthy subjects. NPv patients had estimated Vc 17.5% 
higher than non-NPv patients. All fixed effect parameters were estimated with good precision, with 
%RSEs generally <29%, except for the NPv effect on Vc (53.3%). Inter-individual random effects, with 
correlation parameters estimated between CL, Vc, Vp and Q were also well estimated, with all %RSEs 
<18%. Correlation between some of the random effect parameters was high (–0.36 < r2 < 0.99). 
 
Exploratory exposure-response analysis 
The exposure-response analyses included 359 cIAI patients, 420 cUTI patients and 124 NP patients 
who had one or more aerobic Gram-negative pathogen isolated at baseline. Almost all individual 
ceftazidime %fT>MIC ceftazidime-avibactam and avibactam %fT >CT values were close to 100%. The 
low treatment failure rates in the Phase III trials limited investigation of clinical PK/PD relationships, 
and no meaningful exposure-response relationships were observed. Higher avibactam CT targets and 
CT targets corrected for MIC in the presence and absence of avibactam were investigated as an 
exploratory analysis; again, there were no meaningful exposure-response relationships noted. 
Unfavorable OMR was relatively infrequent among cIAI and cUTI patients (5.8% and 15.5% 
respectively) but more prevalent among NP patients (38.7%). 
 
Individual predicted exposures and joint PK/PD target attainment in Phase III patients 
Ceftazidime exposures were similar in cUTI and NP patients, and lower in cIAI patients (up to 23.0% 
lower AUCss,0–24; Table 3). Avibactam exposures were similar in cUTI and cIAI patients and higher in 
NP patients (up to 28.0% higher AUCss,0–24). VAP patients had approximately 20% lower AUCss,0–24 and 
Cmax,ss for both ceftazidime and avibactam than non-VAP patients, reflecting their higher Vc and CrCL. 
Actual joint PK/PD target attainment rates (50% fT>8 mg/L for ceftazidime and 50% fT>1 mg/L for 
avibactam) were >97% for cIAI, cUTI and NP, including VAP and non-VAP subgroups (Table 3). Joint 
target attainment rates were >93% across all other evaluated subgroups, except for the 8–15 
mL/min renal function group (n=4), which was too small for meaningful comparison (Table 3). 
Exposure and joint target attainment rates were comparable among patients with and without 
baseline bacteremia, APACHE II score >10, SIRS at baseline, fever at baseline, or concomitant use of 
OAT1/OAT3 inhibitor(s), with Cmax,ss and AUCss,0–24 differing by ≤25%. Age- or obesity-related changes 
in exposure appeared to be adequately captured by changes in CrCL. For high CrCL, AUCss,0–24 
decreased, however, joint target attainment remained >95% in the 150–180 mL/min and 180–395 
mL/min subgroups, reflecting the relatively small increases in ceftazidime and avibactam clearance 
at higher CrCL. Japanese patients had higher ceftazidime and avibactam exposure than the 
Caucasian/Other reference population and achieved 100% joint target attainment. 
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Exposure and PTA simulations 
For simulated patients with normal renal function (CrCL >80 mL/min), geometric mean exposure 
parameters for ceftazidime differed by <10% in the cIAI, NPv, and VAP populations. Compared with 
cIAI patients, ceftazidime geometric mean Cmax,ss and AUCss,0–24 were 19% and 29% higher for cUTI 
patients, respectively, and 24% and 31% higher for non-VAP patients, respectively (Table 4). 
Simulated avibactam exposure parameters differed by <10% across cIAI, cUTI, NPv and VAP patient 
populations with normal renal function (Table 4). Non-VAP patients had higher avibactam exposures, 
with geometric mean Cmax,ss and AUCss,0–24 28% and 36% higher, respectively, than cIAI patients 
(Table 4). For NP patients overall, avibactam Cmax,ss and AUCss,0–24 were 11% and 21% higher, 
respectively, than for cIAI patients, reflecting the contribution of the non-VAP subset. 
Across all indications, patients with mild renal impairment (CrCL 51 to <80 mL/min) had higher 
predicted ceftazidime and avibactam exposure parameters than those with normal renal function 
receiving the same dose (Table 4). Patients with moderate (CrCL 31 to <50 mL/min) or severe (CrCL 6 
to <30 mL/min) renal impairment receiving the appropriate label dose adjustments had lower 
predicted ceftazidime and avibactam Cmax,ss than those with normal renal function, while maintaining 
slightly higher AUCss,0–24. In dose-adjusted patients with ESRD, simulated ceftazidime Cmax,ss and 
AUCss,0–24, were 139–156% and 220–238%, respectively higher than in patients with normal renal 
function; for avibactam these values were 80–87% and 101–111%, respectively higher. Simulations 
for the ESRD population did not account for drug removal through hemodialysis, hence these high 
exposures represent a worst-case scenario. PTA simulations demonstrated that PTA exceeded 94.9% 
at a ceftazidime-avibactam MIC of 8 mg/L across all indications and renal function subgroups (Table 
4). Joint PTA plotted as a function of ceftazidime-avibactam MIC in simulated cIAI, cUTI and NP 
patients with normal renal function is shown in Figure 3. >90% PTA was maintained for more joint 
stringent targets up to 60% fT>8 mg/L for ceftazidime and 60% fT>1 mg/L for avibactam (data not 
shown). 
 
Discussion 
PopPK modelling of antimicrobial therapies, and simulations for PTA analysis, are recognized 
techniques for optimizing dosing for efficacy and safety.40, 41 They also play a role in the 
determination of interpretative criteria (breakpoints), particularly when pathogens isolated in 
clinical studies have a limited range of MICs.42 
These PopPK models for ceftazidime and avibactam described well the PK of both drugs in Phase III 
cIAI, cUTI and NP patients. The main factors influencing variability in exposure of both avibactam and 
ceftazidime, primarily renal function, were well-characterized. The final models were qualified using 
VPCs and deemed suitable for use in PTA simulations. Major strengths of the modelling include the 
inclusion of a high proportion of patient PK data, the inclusion of subjects with renal function varying 
from ARC to ESRD, and the comprehensive set of covariates examined. Ceftazidime and avibactam 
are predominately excreted by the kidneys, so understanding the effects of reduced and augmented 
renal function on exposure is vital. Examining covariates relating to critical illness and septic shock 
was also important because these can significantly affect the volume of distribution and exposure of 
many other antimicrobial agents.43-46 
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The PopPK models accurately predicted exposure in patients with varying degrees of renal function: 
clearance of both avibactam and ceftazidime was close to proportional at CrCL <80 mL/min and <100 
mL/min respectively, and at higher CrCL values, drug clearance increased only modestly with 
increasing CrCL. Comparison of the model-predicted AUCss0–24 between Phase III patients across all 
indications with normal renal function and those with mean estimated CrCL >150 mL/min showed 
that small reductions in ceftazidime and avibactam exposure in patients with high CrCL had no 
impact on target attainment rates, which were >95.7%. These data confirm the final dosing 
recommendations using exposure and PTA data from all Phase III trials,47 and indicate that dose 
adjustments are only necessary for patients with CrCL <50 mL/min, in whom clearance of 
ceftazidime and avibactam is appreciably reduced; dose adjustments are not warranted for patients 
with ARC. 
In Phase III patients, individual target attainment at a ceftazidime-avibactam MIC of 8 mg/L 
exceeded 97% in all indications, as well as other subgroups of potential clinical significance including 
obesity, SIRS, fever, elevated WBCs, concomitant OAT1/OAT3 inhibitors and bacteremia. This 
reflects the limited impact of covariates other than CrCL on ceftazidime and avibactam exposure, 
and demonstrates that the ceftazidime-avibactam dosage regimen of 2000-500 mg q8h for patients 
with CrCL >50 mL/min provides appropriate plasma concentration profiles for nearly all patients, 
including those with severe systemic disturbances, advanced age, high CrCL and obesity. 
In PTA simulations using the updated PopPK models, the proposed ceftazidime-avibactam regimens, 
including dose adjustments for renal impairment, provided PTA >90% in every patient subgroup 
studied in Phase III across cUTI, cIAI and NP (including HAP and VAP) indications. PTA simulations 
were performed using re-inflated post-hoc PK parameters to account for shrinkage, which is a more 
conservative approach than generally applied. In addition, calculations were based on a robust joint 
target, providing a high degree of confidence that both ceftazidime and avibactam will reach 
required plasma concentrations. A >90% PTA for the joint PK/PD target of ≥50% fT>8 mg/L for 
ceftazidime and ≥50% fT>CT of 1 mg/L for avibactam supports a ceftazidime-avibactam MIC 
breakpoint of 8 mg/L against both Enterobacteriaceae and Pseudomonas aeruginosa. Of note, the 
modelling of β-lactam/β-lactamase inhibitor combinations is an evolving field with various 
approaches being adopted by the sponsors of different recently developed combinations and those 
currently in investigation. Our approach involved defining fixed joint PK-PD targets that were 
conservative with respect to the exposure levels assumed to be required for clinical efficacy. Other 
investigators have started to develop mechanistic-based modelling approaches, including for the 
ceftazidime-avibactam combination.48-50  
In conclusion, PopPK models of ceftazidime and avibactam incorporating Phase III data from patients 
with cIAI, cUTI, and NP, found several covariates influence variability in exposure to both agents. 
However, CrCL was the only covariate with a sufficiently large effect to warrant dose adjustments. 
These analyses provide confidence that the approved ceftazidime-avibactam dosage regimens 
(including adjustments for CrCL ≤50 mL/min), provide sufficient exposures for patients with all 
approved indications and across a range of clinical circumstances considered challenging for other 
antibiotics, such as bacteremia, SIRS, obesity, ARC, and mechanical ventilation.  
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Study highlights 
What is the current knowledge on the topic? 
PopPK models of ceftazidime and avibactam in patients with complicated intra-abdominal infection 
(cIAI) and complicated urinary tract infection (cUTI) which showed that creatinine clearance is the 
key covariate determining clearance were used to support dose selection and adjustments for 
patients with renal impairment in Phase III trials. 
What question did this study address? 
What is the impact of different patient covariates and infections/site of infections, including 
nosocomial pneumonia, bacteremia and augmented renal clearance, on ceftazidime and avibactam 
PK and on the probability of pharmacodynamic target attainment? 
What does this study add to our knowledge? 
PTAs derived from population PK modelling incorporating data from Phase III trials were >90% across 
all indications (cIAI, cUTI including pyelonephritis and nosocomial pneumonia including ventilator-
associated pneumonia) and patient subgroups, and supported an MIC breakpoint of 8 mg/L against 
Enterobacteriaceae and Pseudomonas aeruginosa.  
How might this change clinical pharmacology or translational science? 
These analyses demonstrate the value of population PK models and joint PTA simulations to guide 
combination drug (e.g. antibiotic and inhibitor) development decisions. 
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Figure legends 
Figure 1. Prediction-corrected visual predictive check stratified by population for ceftazidime 
Solid lines represent medians and 10th and 90th percentiles of observed data. Shaded regions encompass 90% 
of the simulated (n=1000) values of the predicted medians (red) and 10th and 90th percentiles (blue) Data 
points represent the observed data (ng/mL) 
 
CI, confidence interval; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; 
non-VAP, not ventilator-associated pneumonia; NP, nosocomial pneumonia; Obs, observations; VAP, 
ventilator-associated pneumonia 
 
Figure 2. Prediction-corrected visual predictive check stratified by population for avibactam  
Solid lines represent the median of the observed data. Shaded regions encompass 90% of the simulated 
(n=5000) values of the predicted medians, 5th, and 95th percentiles. Data points represent the observed data 
(ng/mL) 
AVI, avibactam; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; non-
VAP, not ventilator-associated pneumonia; NP, nosocomial pneumonia; VAP, ventilator-associated pneumonia 
Figure 3.  Simulated joint PTA as function of ceftazidime-avibactam MIC in 5000 simulated cIAI, 
cUTI or NP patients with normal renal function receiving ceftazidime-avibactam 2000-500 mg 
every 8 hours  
cIAI, complicated intra-abdominal infection; MIC, minimum inhibitory concentration; NP, nosocomial pneumonia; PTA, 
probability of target attainment 
Joint target attainment was defined as 50% fT >8 mg/L for ceftazidime, and 50%fT >1 mg/L for avibactam 
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Table 1. Parameter estimates for the final ceftazidime population PK model 
 
Parameter (units) Estimate %RSE BSV (CV%) 
Slope1: CrCL <100 mL/min, slope1*CrCL 0.0103036 0.409 NA 
Slope2: CrCL ≥100 mL/min, slope1*100 + slope2*(CrCL–100) 0.001252 8.84 NA 
θ1: CL (L/h) 6.95 1.7 42.3 
θ2: Vc (L) 10.5 13.1 105 
θ3: Q (L/h) 31.5 18.8 259 
θ4: Vp (L) 7.57 9 110 
θ5: Population effect on CL (cIAI) 1.16 2.2 NA 
θ6: Population effect on CL (NP) 0.999 2.4 NA 
θ7: Race effect on CL (ASN) –0.161 11.8 NA 
θ8: Race effect on CL  –0.0855 27 NA 
θ9: Population effect on Vc (cUTI) 1.03 11.1 NA 
θ10: Population effect on Vc (cIAI or NP) 1.14 9.9 NA 
θ11: Population effect on Vc (cUTI/acute pyelonephritis) –0.185 41.2 NA 
θ12: Race effect on Vc (ASN, CHN, JPN) –0.27 18.6 NA 
θ13: WT effect on Vc 1.01 12.6 NA 
θ14: Population effect on Vc (NPv) 0.297 45.4 NA 
  
  
Shrinkage (%) or 
correlation† 
KCL2 0.179 3.3 11.4 
KVc2 1.10 10.2 31.2 
-KVc -KCL covariance‡ –0.189 15.2 r = –0.42 
KVp2 1.21 8.8 17.5 
KVp -KCL covariance‡   0.383 5.1 r = 0.82 
KVp -KVc covariance‡   –0.972 7.3 r = –0.84 
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KQ2 6.70 15.5 27.46 
KQ -KCL covariance‡   0.883 10.1 r = 0.81 
KQ -KVc covariance‡   –0.643 43.1 r = –0.24 
KQ-KVp covariance‡   1.73 14.5 r = 0.61 
Residual noise    
Proportional error, Phase I‡ 0.04 0.5 2.9 
Additive error, Phase I‡ 26489 7.5 2.9 
Proportional error, Phase II and Phase III‡ 0.114 2.1 9.5 
Additive error, Phase II and Phase III‡ 18.4 447 9.5 
 
†Correlation coefficient (r) between random effects; ‡Reported as variance. 
 
ASN, non-Japanese, non-Chinese Asian; BSV, between-subject variability; CHN, Chinese; cIAI, complicated 
intra-abdominal infection; CL, clearance; CrCL, creatinine clearance; cUTI, complicated urinary tract infection; 
%CV, coefficient of variation; JPN, Japanese; NA, not assessed; NP, nosocomial pneumonia; NPv, nosocomial 
pneumonia with the presence of a ventilator in the hospital room on the day of pharmacokinetic sampling, 
which includes ventilator-associated pneumonia and hospital-acquired pneumonia in patients who were 
receiving ventilation on the day of sampling; Q, inter-compartmental clearance; %RSE, % relative standard 
error; Vc, volume of the central compartment; Vp, volume of the peripheral compartment; WT, body weight. 
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Table 2. Parameter estimates for the final avibactam population PK model 
 
Parameter (units) Estimate %RSE BSV (CV%) 
θ1: CL (L/h) 10.2 1.8 59.1 
θ2: Vc (L) 11.1 9.9 107.1 
θ3: Q (L/h) 5.44 13.9 122.2 
θ4: Vp (L) 6.91 6.5 252.2 
θ5: CL estimate for ESRD patients 0.0678 8.3 NA 
θ6: CL estimate for dialysis patients 20.8 9.6 NA 
θ7: Power CrCL (<80) on CL 1.05 2.4 NA 
θ8: Linear CrCL (≥80) on CL 0.00279 3.7 NA 
θ9: Population effect on Vc (cIAI, Phase II), Vc*(1+T9) 1.92 25.4 NA 
θ10: Population effect on CL (cIAI, Phase II), CL*(1+T) 0.406 23.2 NA 
θ11: Population effect on Vc (cUTI), Vc*(1+T11) 0.434 24 NA 
θ12: Population effect on Vc (cIAI, Phase III, NP), Vc*(1+T11) 0.329 28.6 NA 
θ13: Scaling factor for CrCL in subjects with ARC, CL=TVCL*(1+T8*T13* 
[CrCL–80]) 
0.992 17.4 NA 
θ14: WT on Vc (WT/70.0)
θ14 1.08 7.8 NA 
θ15: APACHE II on CL, CL*(1+T15) -0.197 8.7 NA 
θ 22: ASN on CL, CL*(1+T22) -0.0865 20.2 NA 
θ 28: NPv on Vc ,Vc*(1+T28) 0.175 53.3 NA 
  
  
Shrinkage (%)† 
KCL2 0.349 2 7.29 
KVc2 1.147 6 28.15 
KVc -KCL‡ 0.125 15.6 r = 0.2 
KVp2 1.494 7 13.52 
KVp -KCL‡   0.611 3.6 r = 0.85 
KVp -KVc‡   –0.426 18 r = –0.33 
KQ2 6.359 8.1 14.18 
KQ -KCL‡   1.231 4.1 r = 0.83 
KQ -KVc‡   –0.978 16.8 r = –0.36 
KQ-KVp‡   3.059 7.1 r = 0.99 
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Residual noise    
θ17: Proportional error, Phase I
  0.173 0.1 NA 
θ18: Additive variability, Phase I 44.6 0.5 NA 
θ19: Proportional variability, Phase II 0.492 3 NA 
θ 20: Proportional variability, Phase III 0.363 1.1 NA 
 
†Correlation coefficient (r) between random effects; ‡Reported as variance. 
ARC, augmented renal clearance; ASN, non-Japanese, non-Chinese Asian; BSV, between-subject variability; 
CHN, Chinese; CI, confidence interval; cIAI, complicated intra-abdominal infection; CL, clearance; CrCL, 
creatinine clearance; cUTI, complicated urinary tract infection; %CV, coefficient of variation; ESRD, end-stage 
renal disease; JPN, Japanese; K, individual random subject effect; NA, not assessed; NP, nosocomial 
pneumonia; NPv, nosocomial pneumonia with the presence of a ventilator in the hospital room on the day of 
pharmacokinetic sampling, which includes ventilator-associated pneumonia and hospital-acquired pneumonia 
in patients who were receiving ventilation on the day of sampling; θ, typical value of pharmacokinetic 
parameter; Q, inter-compartmental clearance; %RSE, % relative standard error; Vc, volume of the central 
compartment; Vp, volume of the peripheral compartment; WT, body weight. 
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Table 3. Individual predicted ceftazidime and avibactam steady-state exposures and joint PK/PD 
target attainment for subgroups of actual Phase III cIAI, cUTI and NP patients 
 
 n Ceftazidime Avibactam Joint PK/PD 
target 
attainment 
rate, % (95% 
CI)† 
Cmax,ss 
geometric 
mean (CV), 
mg/L 
AUCss,0–24 
geometric 
mean (CV), 
m·h/L 
Cmax,ss 
geometric 
mean (CV), 
mg/L 
AUCss,0–24 
geometric 
mean (CV), 
m·h/L 
Patient population 
cUTI 648 77.9 (114.2) 979 (119.7) 12.1 (161.9) 138 (164.1) 98.5 (97.5, 
99.4) 
cIAI 703 66.9 (105.0) 749 (114.0) 12.8 (155.3) 132 (152.0) 98.6 (97.7, 
99.5) 
NP 413 72.9 (125.2) 950 (131.0) 14.2 (166.1) 169 (168.5) 99.0 (98.1, 
100.0) 
Non-VAP 275 79.0 (120.0) 1016 (122.0) 15.5 (166.9) 183 (168.7) 99.6 (98.9, 
100.0) 
VAP 138 61.9 (127.0) 830 (142.7) 12 (157.6) 146 (163.0) 97.8 (95.4, 
100.0) 
Bacteremia at baseline 
No 146
5 
71.9 (116.1) 881 (125.5) 12.6 (157.3) 141 (161.2) 98.6 (98.0, 
99.2) 
Yes 88 73.6 (102.8) 919 (120.1) 14.2 (164.1) 161 (161.3) 100.0 (NA) 
Baseline APACHE II score 
≤10 677 67.0 (105.0) 748 (113.8) 12.7 (154.3) 131 (150.6) 98.5 (97.6, 
99.4) 
>10 438 72.3 (124.3) 938 (130.9) 14.3 (167.0) 170 (168.7) 99.1 (98.2, 
100.0) 
Missing‡ 649 77.9 (114.1) 979 (119.7) 12.1 (161.8) 138 (164.0) 98.5 (97.5, 
99.4) 
SIRS at baseline 
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No 770 72.3 (108.9) 895 (120.5) 12.8 (159.2) 143 (162.0) 99.1 (98.4, 
99.8) 
Yes 773 71.5 (121.3) 869 (129.7) 12.6 (157.1) 142 (161.3) 98.3 (97.4, 
99.2) 
Missing 10 83.5 (130.2) 977 (123.7) 12.1 (115.1) 129 (116.4) 100.0 (NA) 
Baseline WBC count (cells/µL) 
≤12000 876 74.6 (110.9) 923 (118.9) 12.8 (159.1) 145 (161.7) 98.9 (98.2, 
99.6) 
>12000 486 67.6 (119.4) 801 (128.4) 12.5 (160.4) 136 (161.5) 98.6 (97.5, 
99.6) 
Missing 191 72.0 (121.4) 924 (136.8) 12.3 (145.3) 147 (158.6) 98.4 (96.7, 
100.0) 
Fever at baseline 
No 116
6 
71.9 (113.4) 888 (123.9) 12.9 (154.5) 146 (159.2) 99.1 (98.5, 
99.6) 
Yes 343 72.1 (121.8) 859 (130.3) 12.2 (165.7) 134 (167.4) 98.3 (96.9, 
99.6) 
Missing 44 75.1 (117.3) 929 (118.4) 11.8 (180.9) 132 (164.7) 93.2 (85.7, 
100.0) 
Age (years) 
18 to 65 119
2 
70.0 (113.5) 800 (122.7) 12.5 (167.1) 131 (166.8) 98.4 (97.7, 
99.1) 
>65 to 75 284 77.1 (109.4) 997 (107.6) 13.2 (119.0) 156 (118.4) 99.6 (99.0, 
100.0) 
>75 to 89 288 76.8 (120.5) 1102 (120.6) 14.0 (169.6) 180 (164.7) 98.6 (97.3, 
100.0) 
Concomitant use of OAT1/OAT3 inhibitor(s) 
No 163
1 
71.7 (115.2) 869 (124.4) 12.8 (160.5) 142 (162.3) 98.6 (98.0, 
99.2) 
Yes 133 78.5 (103.5) 934 (114.7) 13.7 (165.4) 150 (158.5) 99.2 (97.8, 
100.0) 
Obesity 
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Normal 144
1 
73.0 (115.5) 878 (124.2) 13.0 (160.2) 144 (161.4) 98.7 (98.1, 
99.3) 
Obesity I (29.9 ≤ 
BMI <34.9 kg/m2) 
208 67.9 (111.8) 841 (125.2) 12.0 (178.4) 136 (179.1) 97.6 (95.5, 
99.7) 
Obesity II (34.9 ≤ 
BMI <39.9 kg/m2) 
74 73.7 (109.6) 894 (115.2) 13.2 (139.7) 141 (140.0) 100.0 (NA) 
Obesity III (BMI 
≥39.9 kg/m2) 
32 64.2 (93.6) 806 (119.4) 9.7 (116.9) 115 (128.5) 100.0 (NA) 
Missing 9 70.9 (87.0) 959 (106.5) 14.2 (83.4) 172 (112.8) 100.0 (NA) 
Race 
Caucasian/Other 120
9 
68.6 (112.9) 848 (125.0) 12 (159.4) 135 (161.3) 98.3 (97.6, 
99.1) 
Asian (non-
Chinese; non-
Japanese) 
248 82.2 (118.4) 968 (121.9) 14.9 (166.5) 166 (170.8) 99.6 (98.8, 
100.0) 
Chinese and 
Taiwanese 
262 77.6 (112.5) 884 (120.5) 14.7 (154.9) 151 (155.1) 98.9 (97.6, 
100.0) 
Japanese 45 90.4 (82.6) 1021 (94.8) 16.1 (134.3) 164 (130.9) 100.0 (NA) 
Asian population 
China (only) 251 78.4 (111.2) 892 (119.6) 14.9 (155.6) 153 (155.8) 98.8 (97.5, 
100.0) 
Japan 45 90.4 (82.6) 1021 (94.8) 16.1 (134.3) 164 (130.9) 100.0 (NA) 
Korea 77 79.9 (97.2) 952 (106.5) 13.0 (135.9) 144 (138.1) 98.7 (96.2, 
100.0) 
Taiwan 12 59.4 (130.1) 728 (130.3) 10.2 (109.9) 115 (121.5) 100.0 (NA) 
Vietnam 45 78.6 (109.1) 852 (105.2) 14.6 (116.5) 146 (119.9) 100.0 (NA) 
Day 3 CrCL, mL/min (simulated ceftazidime-avibactam treatment regimen)¶ 
8 to 15  
(750/187.5 mg 
q24h) 
4 34.3 (173.3) 551 (121.9) 6.3 (305.6) 86.3 (220.6) 75.0 (32.6, 
100.0) 
>15 to 30  
(750/187.5 mg 
q12h) 
20 50.4 (139.5) 789 (116.5) 10.9 (174.1) 155 (143.6) 100.0 (NA) 
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>30 to 50  
(1000-250 mg 
q8h) 
128 58.8 (120.5) 938 (122.9) 10.2 (147.6) 148 (153.3) 98.4 (96.3, 
100.0) 
>50 to 80  
(2000-500 mg 
q8h) 
418 90.0 (108.0) 1213 (110.4) 15.3 (142.9) 186 (144.5) 99.0 (98.1, 
100.0) 
>80 to 150  
(2000-500 mg 
q8h) 
955 72.9 (105.9) 828 (112.4) 13.2 (165.5) 138 (163.4) 99.0 (98.3, 
99.6) 
>150 to 180  
(2000-500 mg 
q8h) 
123 58.5 (93.0) 652 (112.8) 9.9 (124.5) 103 (137.5) 98.4 (96.1, 
100.0) 
>180 to 610  
(2000-500 mg 
q8h) 
116 51.2 (109.6) 542 (108.1) 9.9 (171.6) 96 (155.9) 95.7 (92.0, 
99.4) 
 
†The joint PK/PD target was defined as 50% fT> 8 mg/L for ceftazidime and 50% fT>1 mg/L for avibactam; 
‡APACHE II scores were collected for cIAI and NP patients only, hence these data were not available for the 648 
cUTI patients; data were missing for 1 cIAI patient; ¶subjects with CrCL <50 ml/min were assumed to receive 
the labelled dosage regimen appropriate to their level of renal insufficiency. 
  
APACHE II, Acute Physiology and Chronic Health Evaluation II; AUCss,0–24 area under the plasma concentration 
versus time curve at steady state BMI, body mass index; CI, confidence interval; cIAI, complicated intra-
abdominal infections; Cmax,ss maximum plasma concentration at steady state; CrCL, creatinine clearance; 
cUTI complicated urinary tract infections; non-VAP, not ventilator-associated pneumonia; CV, coefficient of 
variation; NA, not applicable; NP, nosocomial pneumonia; OAT1/OAT3, organic anion transporter 1/ organic 
anion transporter 3; PK pharmacokinetic; q8h, every 8 hours; q12h, every 12 hours; q24h, every 24 hours; SIRS, 
systemic inflammatory response syndrome; VAP, ventilator-associated pneumonia; WBC, white blood cell. 
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Table 4. Steady-state exposure for ceftazidime and avibactam and probability of joint PK/PD 
target attainment in simulated patients by indication and renal function category 
 
Renal function category 
(CrCL);  
ceftazidime-avibactam 
dosing regimen† 
Patient 
populati
on 
Avibactam Ceftazidime Joint 
PTA, %‡ 
Cmax,ss 
geometric 
mean (CV), 
mg/L 
AUCss,0–24 
geometric 
mean (CV), 
m·h/L 
Cmax,ss 
geometric 
mean (CV), 
mg/L 
AUCss,0–24 
geometric 
mean (CV), 
m·h/L 
Normal (>80 mL/min); 
2000-500 mg q8h 
cIAI 61.1 (44) 683 (45) 11.5 (83) 121 (72) 94.9 
cUTI 73 (47) 880 (49) 11.2 (87) 126 (82) 95.2 
NP 65.4 (53) 805 (55) 12.8 (94) 147 (89) 98.3 
NPv 56.8 (51) 723 (56) 11.2 (82) 131 (75) 97.2 
VAP 55.1 (59) 719 (64) 10.7 (85) 129 (79) 96.1 
Non-VAP 75.7 (43) 894 (48) 14.7 (92) 164 (93) 100.0 
Mild impairment (51 to 
<80 mL/min);  
2000-500 mg q8h 
cIAI 79.6 (44) 1080 (45) 14.3 (84) 172 (71) 99.0 
cUTI 94.5 (48) 1330 (49) 13.6 (88) 172 (82) 98.7 
NP 86 (53) 1260 (55) 16 (95) 211 (87) 98.9 
NPv 76 (52) 1160 (56) 14.2 (82) 193 (73) 98.4 
VAP 74.8 (60) 1160 (62) 13.9 (88) 193 (78) 97.6 
Non-VAP 97.1 (44) 1370 (48) 17.7 (93) 226 (92) 100.0 
Moderate impairment (31 to 
<50 mL/min); 1000-250 mg 
q8h 
cIAI 54.2 (45) 871 (45) 9.82 (86) 143 (72) 99.3 
cUTI 65.5 (49) 1070 (49) 9.49 (90) 142 (83) 99.1 
NP 59.7 (54) 1020 (55) 11.1 (97) 175 (88) 98.8 
NPv 53.4 (54) 940 (56) 9.97 (84) 161 (74) 98.3 
VAP 52.8 (62) 941 (62) 9.77 (90) 160 (78) 97.7 
Non-VAP 66.7 (45) 1110 (48) 12.3 (96) 189 (92) 100.0 
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Severe 1 impairment (16 to 
<30 mL/min); 750-187.5 mg 
q12h 
cIAI 47.6 (46) 768 (47) 8.88 (92) 130 (73) 99.0 
cUTI 57.8 (52) 947 (51) 8.61 (96) 129 (84) 98.6 
NP 52.3 (56) 903 (56) 10 (101) 159 (88) 98.8 
NPv 46.8 (56) 829 (57) 8.96 (88) 146 (75) 97.9 
VAP 46.4 (65) 830 (64) 8.81 (95) 145 (79) 97.3 
Non-VAP 58.4 (46) 982 (50) 11 (100) 171 (93) 100 
Severe 2 impairment (6 to 
<15 mL/min); 750-187.5 mg 
q24h 
cIAI 53.7 (49) 860 (50) 10.4 (100) 151 (76) 99.3 
cUTI 65.5 (56) 1060 (55) 10.1 (104) 150 (89) 98.8 
NP 59.1 (59) 1010 (60) 11.7 (109) 186 (92) 99.2 
NPv 52.6 (61) 924 (62) 10.4 (94) 169 (79) 98.7 
VAP 52.3 (70) 929 (68) 10.3 (102) 170 (84) 98.0 
Non-VAP 65.5 (48) 1090 (55) 12.8 (107) 198 (98) 100.0 
ESRD; 750-187.5 mg q48h cIAI 9.7 (105) 127 (70) 85 (59) 1570 (65) 99.6 
cUTI 9.3 (107) 127 (80) 105 (66) 1940 (70) 99.5 
NP 10.7 (113) 157 (85) 96.1 (70) 1860 (74) 99.5 
NPv 9.5 (95) 143 (71) 87.2 (72) 1720 (75) 99.1 
VAP 9.3 (103) 143 (76) 86.2 (81) 1700 (81) 98.8 
Non-VAP 11.8 (108) 168 (90) 106 (60) 2040 (69) 100.0 
 
†Labelled dose adjustments for patients with renal insufficiency; ‡joint PK/PD target was defined as 50% fT> 8 
mg/L for ceftazidime and 50% fT>1 mg/L for avibactam.  
AUCss,0–24, area under the plasma concentration versus time curve at steady state; cIAI, complicated 
intra-abdominal infection; Cmax,ss, maximum plasma concentration at steady state; cUTI, complicated urinary 
tract infection; CV, coefficient of variation; ESRD, end-stage renal disease; non-VAP, not ventilator-associated 
pneumonia; NP, nosocomial pneumonia; NPv, nosocomial pneumonia with ventilator in the hospital room on 
the day of pharmacokinetic sampling, which includes ventilator-associated pneumonia and hospital-acquired 
pneumonia in patients who were receiving ventilation on the day of sampling; PTA, probability of target 
attainment; q8h, every 8 hours; q12h, every 12 hours; q24h, every 24 hours; q48h, every 48 hours; VAP, 
ventilator-associated pneumonia. 
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